Metformin and Body Mass Index of Patients under Treatment with SSRI

Clinical Trial Of Investigation of Efficacy of Metformin on the Body Mass Index of Patients under Treatment with Selective Serotonin Re uptake Inhibitors Drugs Referred to Psychiatry Clinics of Rasht

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140102016035N3

Enrollment

Registered

2019-07-03

Start date

2019-07-06

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Obesity. Condition 2: Depression. Condition 3: Anxiety Disorders. Drug-induced obesity Major depressive disorder, single episode, severe without psychotic features Other anxiety disorders

Interventions

Intervention 1: Intervention group: The Metformin that produced by the Rohamet Pharmaceutical Company, is given to the intervention group. At baseline, third and sixth month of follow-up, Weight, body

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Obtain informed consent from patients No history of side effects with metformin and SSRI drugs The absence of kidney and liver disorders The absence of a physical illness such as diabetes and Autoimmune disease No taking Corticosteroids Not taking any type of drug and stimulant The absence of psychotic features

Exclusion criteria

Exclusion criteria: Addiction Having metabolic disorders

Design outcomes

Primary

Measure	Time frame
Fasting Blood Glucose. Timepoint: At the start of treatment, in the third and sixth months of follow up, fasting blood glucose (Kate: Pars Test) will be measured by a psychiatrist's assistant and will be recorded in the patient records. Method of measurement: Fasting blood glucose (kits: pars test), are measured by a psychiatrist's assistant.;Cholesterol. Timepoint: At the start of treatment, in the third and sixth months of follow up, Cholesterol (Kate: Pars Test) will be measured by a psychiatrist's assistant and will be recorded in the patient records. Method of measurement: Cholesterol(kits: pars test), are measured by a psychiatrist's assistant.;Triglyceride. Timepoint: At the start of treatment, in the third and sixth months of follow up, Triglyceride (Kate: Pars Test) will be measured by a psychiatrist's assistant and will be recorded in the patient records. Method of measurement: Triglyceride (kits: pars test), are measured by a psychiatrist's assistant.;Height. Timepoint: At the onset of treatment, in the third and sixth months of follow up, the height (By centimeters) will be measured by the assistant psychiatrist. Method of measurement: The height (By centimeters) will be measured by the assistant psychiatrist.;Weight. Timepoint: At the start of treatment, in the third and sixth months of follow-up, the weight (measured by the digital scale of the Race of Germany, with a precision of one tenth kilogram) will be measured by the assistant psychiatrist. Method of measurement: The weight (measured by the digital scale of the Race of Germany, with a precision of one tenth kilogram) will be measured by a psychiatrist's assistant.;Body Mass Index. Timepoint: At the start of treatment, in the third and sixth follow up, the BMI will be measured by the psychiatrist's assistant (by the formula for dividing the body weight per kg by the second strength per meter). Method of measurement: The BMI will be measured by the psychiatrist's assistant (by the formula for divi	—

Measure

Time frame

Fasting Blood Glucose. Timepoint: At the start of treatment, in the third and sixth months of follow up, fasting blood glucose (Kate: Pars Test) will be measured by a psychiatrist's assistant and will be recorded in the patient records. Method of measurement: Fasting blood glucose (kits: pars test), are measured by a psychiatrist's assistant.;Cholesterol. Timepoint: At the start of treatment, in the third and sixth months of follow up, Cholesterol (Kate: Pars Test) will be measured by a psychiatrist's assistant and will be recorded in the patient records. Method of measurement: Cholesterol(kits: pars test), are measured by a psychiatrist's assistant.;Triglyceride. Timepoint: At the start of treatment, in the third and sixth months of follow up, Triglyceride (Kate: Pars Test) will be measured by a psychiatrist's assistant and will be recorded in the patient records. Method of measurement: Triglyceride (kits: pars test), are measured by a psychiatrist's assistant.;Height. Timepoint: At the onset of treatment, in the third and sixth months of follow up, the height (By centimeters) will be measured by the assistant psychiatrist. Method of measurement: The height (By centimeters) will be measured by the assistant psychiatrist.;Weight. Timepoint: At the start of treatment, in the third and sixth months of follow-up, the weight (measured by the digital scale of the Race of Germany, with a precision of one tenth kilogram) will be measured by the assistant psychiatrist. Method of measurement: The weight (measured by the digital scale of the Race of Germany, with a precision of one tenth kilogram) will be measured by a psychiatrist's assistant.;Body Mass Index. Timepoint: At the start of treatment, in the third and sixth follow up, the BMI will be measured by the psychiatrist's assistant (by the formula for dividing the body weight per kg by the second strength per meter). Method of measurement: The BMI will be measured by the psychiatrist's assistant (by the formula for divi

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayeh Shokrgozar

Rasht University of Medical Sciences

Dr.shokrgozar@yahoo.com+98 13 3366 6268

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026